ME03480B - Tretiranje akutne limfoblastne leukemije - Google Patents

Tretiranje akutne limfoblastne leukemije

Info

Publication number
ME03480B
ME03480B MEP-2019-146A MEP2019146A ME03480B ME 03480 B ME03480 B ME 03480B ME P2019146 A MEP2019146 A ME P2019146A ME 03480 B ME03480 B ME 03480B
Authority
ME
Montenegro
Prior art keywords
treatment
lymphoblastic leukemia
acute lymphoblastic
acute
leukemia
Prior art date
Application number
MEP-2019-146A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Gerhard Zugmaier
Evelyn Degenhard
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41692882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03480(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of ME03480B publication Critical patent/ME03480B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-2019-146A 2008-11-07 2009-11-06 Tretiranje akutne limfoblastne leukemije ME03480B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
EP15185767.9A EP2982696B1 (en) 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
ME03480B true ME03480B (me) 2020-01-20

Family

ID=41692882

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-146A ME03480B (me) 2008-11-07 2009-11-06 Tretiranje akutne limfoblastne leukemije
MEP-2015-181A ME02363B (me) 2008-11-07 2009-11-06 Liječenje akutne limfoblastične leukemije

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-181A ME02363B (me) 2008-11-07 2009-11-06 Liječenje akutne limfoblastične leukemije

Country Status (26)

Country Link
US (3) US20130323247A1 (enExample)
EP (2) EP2982696B1 (enExample)
JP (2) JP5647132B2 (enExample)
KR (1) KR101695327B1 (enExample)
CN (2) CN102209728A (enExample)
AU (4) AU2009313040B2 (enExample)
BR (1) BRPI0921482B1 (enExample)
CA (1) CA2742249C (enExample)
CY (2) CY1117033T1 (enExample)
DK (2) DK2342227T3 (enExample)
ES (2) ES2727585T3 (enExample)
HR (2) HRP20151168T1 (enExample)
HU (2) HUE043326T2 (enExample)
IL (1) IL212652A (enExample)
LT (1) LT2982696T (enExample)
ME (2) ME03480B (enExample)
MX (1) MX2011002927A (enExample)
NZ (1) NZ591311A (enExample)
PL (2) PL2982696T3 (enExample)
PT (2) PT2982696T (enExample)
RS (2) RS58827B1 (enExample)
RU (1) RU2536940C2 (enExample)
SI (2) SI2342227T1 (enExample)
SM (2) SMT201900278T1 (enExample)
WO (1) WO2010052014A1 (enExample)
ZA (1) ZA201103255B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976886T3 (pl) * 2005-12-16 2015-06-30 Amgen Res Munich Gmbh Środki i metody do leczenia chorób nowotworowych
CA2742249C (en) * 2008-11-07 2020-07-21 Micromet Ag Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody
AU2010311559B2 (en) 2009-10-27 2016-07-07 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody
LT3018145T (lt) * 2010-10-27 2018-05-10 Amgen Research (Munich) Gmbh Priemonės ir būdai dlbcl gydymui
EP3831386A1 (en) * 2010-11-10 2021-06-09 Amgen Research (Munich) GmbH Prevention of adverse effects caused by cd3 specific binding domains
AU2012247762B2 (en) * 2011-04-28 2017-07-06 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
EP3105252B1 (en) * 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PL3531133T3 (pl) 2014-05-30 2024-01-29 Amgen Research (Munich) Gmbh Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
WO2016109549A1 (en) 2014-12-30 2016-07-07 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
JP7025214B2 (ja) 2015-02-24 2022-02-24 バイオアトラ、エルエルシー 条件的活性型生物学的タンパク質
CN114634943A (zh) * 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
LT3298042T (lt) 2015-05-20 2025-02-10 Amgen Research (Munich) Gmbh B-ląstelių naikinimas kaip diagnostinis žymuo
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CA3044593A1 (en) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
KR20250111232A (ko) 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
KR20210122268A (ko) * 2019-01-30 2021-10-08 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 암 항원을 표적화하는 dna-인코딩된 이중특이적 t-세포 인게이저 및 암 치료에서 사용 방법
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
JP2022537650A (ja) * 2019-06-13 2022-08-29 アムジエン・インコーポレーテツド 生物製剤の製造における自動化された生物量に基づく灌流制御
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
IL311714A (en) 2021-10-15 2024-05-01 Amgen Res Munich Gmbh Subcutaneous administration of antibodies that engage CD19-binding T cells
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
RU2005141512A (ru) * 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
PL1976886T3 (pl) 2005-12-16 2015-06-30 Amgen Res Munich Gmbh Środki i metody do leczenia chorób nowotworowych
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2742249C (en) * 2008-11-07 2020-07-21 Micromet Ag Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
CA2936120A1 (en) * 2009-01-19 2010-07-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
AU2010311559B2 (en) * 2009-10-27 2016-07-07 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody

Also Published As

Publication number Publication date
DK2342227T3 (en) 2016-02-15
RU2011122819A (ru) 2012-12-20
SMT201900278T1 (it) 2019-07-11
AU2015238784A1 (en) 2015-10-29
HRP20151168T1 (hr) 2015-12-04
PL2342227T3 (pl) 2016-04-29
CY1122366T1 (el) 2021-01-27
US20130323247A1 (en) 2013-12-05
IL212652A (en) 2015-05-31
JP2015057417A (ja) 2015-03-26
CN107184977A (zh) 2017-09-22
HK1158668A1 (en) 2012-07-20
HRP20190912T1 (hr) 2019-07-26
KR20110091668A (ko) 2011-08-12
AU2017219083A1 (en) 2017-09-14
JP2012508164A (ja) 2012-04-05
EP2982696B1 (en) 2019-03-27
US20190300609A1 (en) 2019-10-03
PT2982696T (pt) 2019-06-04
US11597766B2 (en) 2023-03-07
PL2982696T3 (pl) 2019-08-30
MX2011002927A (es) 2011-04-11
RU2536940C2 (ru) 2014-12-27
SMT201500328B (it) 2016-02-25
RS58827B1 (sr) 2019-07-31
NZ591311A (en) 2012-10-26
AU2018260815A1 (en) 2018-11-22
WO2010052014A1 (en) 2010-05-14
HK1220705A1 (en) 2017-05-12
ME02363B (me) 2016-06-20
US20240109964A1 (en) 2024-04-04
HUE043326T2 (hu) 2019-08-28
CN102209728A (zh) 2011-10-05
BRPI0921482A8 (pt) 2017-07-11
CA2742249A1 (en) 2010-05-14
HUE028175T2 (en) 2016-12-28
AU2017219083B2 (en) 2018-08-09
AU2009313040A1 (en) 2010-05-14
JP5647132B2 (ja) 2014-12-24
SI2982696T1 (sl) 2019-06-28
ZA201103255B (en) 2013-12-23
EP2342227B1 (en) 2015-10-07
KR101695327B1 (ko) 2017-01-11
AU2018260815B2 (en) 2020-03-05
BRPI0921482A2 (pt) 2016-01-12
EP2342227A1 (en) 2011-07-13
RS54456B1 (sr) 2016-06-30
EP2982696A3 (en) 2016-02-17
IL212652A0 (en) 2011-07-31
PT2342227E (pt) 2015-11-13
BRPI0921482B1 (pt) 2022-09-20
ES2727585T3 (es) 2019-10-17
CA2742249C (en) 2020-07-21
LT2982696T (lt) 2019-06-10
CY1117033T1 (el) 2017-04-05
AU2009313040B2 (en) 2015-07-09
EP2982696A2 (en) 2016-02-10
DK2982696T3 (da) 2019-05-27
JP5955921B2 (ja) 2016-07-20
ES2558434T3 (es) 2016-02-04
SI2342227T1 (sl) 2015-12-31

Similar Documents

Publication Publication Date Title
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
IL212651A0 (en) Treatment of pediatric acute lymphoblastic leukemia
IL248204A0 (en) Combined treatment of tumors expressing 38cd
ZA201006648B (en) Methods of treatment
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
GB0818074D0 (en) Treatment of biofilms
GB0822011D0 (en) Treatment
GB0811992D0 (en) Treatment
ZA201000225B (en) Treatment of depression
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB2460445B (en) Treatment of ringworm
GB0809319D0 (en) The treatment of puritus
GB0700969D0 (en) Methods of treatment
GB0625602D0 (en) Treatment of sialorrhoea
GB0821093D0 (en) Treatment
GB0816892D0 (en) Treatment
GB0820379D0 (en) Treatment
GB0820534D0 (en) Treatment
GB0712513D0 (en) Treatment of cancer